At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 304 enrolled
Drug / intervention
CD5789 25 µg/g cream +4 moredrug
Likely dose
CD5789 25 µg/g creamfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating CD5789 25 µg/g cream, CD5789 50 µg/g cream, and 3 other interventions for Acne Vulgaris. Completed, enrolled 304 participants across 24 sites.
Detailed Summary
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJun 2012
Primary CompletionJul 2013
Study CompletionJun 2014
TodayJul 2026
First PostedJun 12, 2012
Enrollment StartJun 20, 2012
Primary CompletionJul 24, 2013
Study CompletionJun 12, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.1 years ago
Interventions
CD5789 25 µg/g creamdrug
CD5789 25 µg/g cream applied once daily
CD5789 50 µg/g creamdrug
CD5789 50 µg/g cream applied once daily
CD5789 100 µg/g creamdrug
CD5789 100 µg/g cream applied once daily
Tazarotene 0.1% geldrug
Tazarotene 0.1% gel applied once daily
Vehicle creamdrug
Vehicle cream applied once daily